Dakshidin CEO Joins GenBio CEO on Podcast to Discuss Entering 191 Billion Dollar Anti-Inflammatory Market, Their Strategic Partnership and Research Potential ACCESSWIRE 21 May 2021, 00:05 GMT+10 SAN FRANCISCO, CA / ACCESSWIRE / May 20, 2021 / Dakshidin Corp (OTC PINK:DKSC) CEO Chris Haigh and Giles Tilley, Managing Director of GenBio Inc. an early-stage Biotechnology Company joined Stock Day host Everett Jolly for an interview. 'How did you get involved with GenBio?', Jolly asked Haigh. 'It was prior to the epidemic to start with,' explained Haigh. 'I was introduced to Giles by a mutual acquaintance who thought that there was a synergy between us,' he continued, noting that Dakshidin is in the process of being renamed 'Whitechapel Holdings'. 'Whitechapel is very involved, and has been for a long time, in the health and wellness space, but completely organic and natural,' said Haigh.